Cargando…
MyCTC chip: microfluidic-based drug screen with patient-derived tumour cells from liquid biopsies
Cancer patients with advanced disease are characterized by intrinsic challenges in predicting drug response patterns, often leading to ineffective treatment. Current clinical practice for treatment decision-making is commonly based on primary or secondary tumour biopsies, yet when disease progressio...
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763115/ https://www.ncbi.nlm.nih.gov/pubmed/36561926 http://dx.doi.org/10.1038/s41378-022-00467-y |